In earnings' conference call, Jhunjhunwala who currently holds 1.12 percent stake in the company threw a volley of questions to the management. The big bull raised questions on Aurobindo Pharma's finance cost, capex, rationale behind investment in vaccines, product launch, potential revenue growth and its fund raising plans.
first published: Aug 24, 2016 02:33 pm
A collection of the most-viewed Moneycontrol videos.
